Mumbai based company,BDR signs pact with Cipla for remdesivir
Team Udayavani, Jun 1, 2020, 6:09 PM IST
BDR Pharmaceuticals has signed a contract-manufacturing deal with Cipla for remdesivir, a patented product of US company Gilead Sciences.
Earlier, The Mumbai-based company had sought the s approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead.
Now BDR has signed a contract to make the drug for Cipla, which is one of the licensed companies.
Gilead has signed voluntary licensing agreements with Cipla, Hetero Labs and Jubilant Life Sciences for the manufacture and sale of remdesivir in 127 poor and middle-income nations including India.
Dharmesh Shah, MD of BDR said, “Nothing is more important than accessibility and affordability for Covid-19 patients and if remdesivir is working, it should be available soon”
However, It is still not known if Gilead has permitted its licensees to enter into sub-licensing manufacturing contracts.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Reverse migration has begun, says FM Nirmala Sitharaman
Markets sustain winning streak — Sensex jumps over 560 points, Nifty tops 22,300-level
Sensex climbs 640 points, Nifty tops 22,300-level in early trade
Insurance regulator IRDAI abolishes age restriction on health insurance product
Elon Musk says India visit delayed due to Tesla obligations
MUST WATCH
Latest Additions
Intense heat wave in eastern states spreads to south India
Sexual harassment case against ex-WFI chief: Court to pass order on closure report on May 20
Modi is ‘Vish Guru’, never respected ‘magalsutra’: Jairam Ramesh
TCS World 10K: New starting point, meticulous arrangements in place
Congress complains to EC, alleges ‘misinformation’ by BJP about manifesto